DSIP (Delta Sleep-Inducing Peptide)
A neuropeptide that promotes delta wave sleep and has stress-protective, pain-modulating, and hormone-regulating properties.
Common Dosage
100mcg - 300mcg before bed
Category
Sleep
- Deep sleep promotion
- Stress reduction
- Pain modulation
- Hormone regulation
DSIP (Delta Sleep-Inducing Peptide) is a neuropeptide originally isolated from the venous blood of sleeping rabbits by Marcel Monnier and colleagues at the University of Basel in 1977. The original hypothesis was that it was a specific 'sleep factor' responsible for initiating sleep. Subsequently, research revealed more complex roles including stress modulation, pain regulation, hormonal balance, and antioxidant effects. It occurs naturally in the human body and brain, with levels fluctuating in relation to the sleep-wake cycle.
DSIP has multiple proposed mechanisms: it modulates voltage-gated calcium channels, has opioid-like analgesic effects through DSIP-specific receptors, influences somatostatin signaling to modulate GH secretion, and appears to regulate the HPA (hypothalamic-pituitary-adrenal) axis stress response. The delta wave sleep induction for which it is named may reflect its modulation of GABAergic and serotonergic pathways involved in sleep architecture.
- Chronic insomnia and sleep architecture normalization
- Stress and cortisol dysregulation management
- Pain modulation research
- Alcohol and opiate withdrawal support
- Delta wave sleep promotion
- GH pulse enhancement via somatostatin modulation
Insomnia and Sleep Architecture
Studies in subjects with chronic insomnia showed DSIP improving sleep onset latency, increasing slow-wave sleep percentage, and normalizing disrupted sleep patterns — effects consistent with both delta wave promotion and HPA axis modulation.
Withdrawal Support
Russian clinical studies explored DSIP in alcohol withdrawal, demonstrating reduced withdrawal severity scores and improved sleep quality during detoxification — consistent with its GABAergic and HPA-modulating effects.
Combined with Ipamorelin
Some practitioners combine DSIP with Ipamorelin at bedtime, hypothesizing that DSIP's somatostatin-modulating effect combines with Ipamorelin's GHRP activity for enhanced nighttime GH release and sleep quality.
- Vivid dreams are commonly reported — can be intense and potentially disturbing for some users
- Headache is reported, particularly in the initial doses
- Long-term effects on endogenous sleep regulation — whether DSIP use disrupts natural DSIP production — is unknown
- Stability is poor — DSIP degrades relatively quickly after reconstitution
- Human clinical trial data outside Russia is very limited
- Headache (rare)
- Vivid dreams